GDRX
HealthcareGoodRx Holdings, Inc. · Medical - Healthcare Information Services · $920M
What is GoodRx Holdings, Inc.?
GoodRx Holdings helps Americans find lower prices on prescription drugs through a free-to-use comparison platform. Headquartered in Santa Monica, California, the company connects consumers with negotiated pharmacy pricing across the United States.
GoodRx operates a prescription price comparison platform that shows consumers geographically relevant drug prices and provides access to negotiated discounts via GoodRx codes redeemable at pharmacies nationwide. Beyond price comparison, the company generates revenue through subscription plans, pharmaceutical manufacturer solutions, and telehealth services. It works alongside pharmacy benefit managers to facilitate pricing between consumers and pharmacies, positioning itself as a consumer-facing layer in the prescription drug supply chain.
GoodRx was incorporated in 2015 and is headquartered in Santa Monica, California.
- Prescription price comparison platform with GoodRx codes
- GoodRx Gold subscription plan for deeper savings
- Pharma manufacturer solutions and advertising products
- Telehealth services connecting patients with providers
- Pharmacy benefit manager integrations for pricing access
Is GDRX a Good Stock to Buy?
UQS Score rates GDRX as Good overall, reflecting a mixed profile across its five quality pillars.
The most notable bright spot in GDRX's profile is its Risk pillar, which rates Strong — suggesting the balance sheet and financial stability hold up well relative to peers. Valuation is rated Attractive, meaning the stock does not appear expensive relative to its fundamentals at current levels.
Growth and Moat are both rated Weak, indicating the company faces meaningful headwinds in expanding its business and lacks a clearly defensible competitive position in the healthcare technology space.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does GDRX pay dividends?
No — GoodRx Holdings, Inc. does not currently pay a dividend.
GoodRx does not currently pay a dividend. As a growth-oriented healthcare technology company, it has prioritized reinvesting resources into platform development, subscriber growth, and expanding its suite of healthcare services rather than returning cash to shareholders through distributions.
When does GDRX report earnings?
GoodRx reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's recent results have reflected the tension between its Attractive valuation and Weak Growth pillar — revenue trends have been under pressure as the prescription discount market evolves. Investors have watched closely for signs of stabilization in its core platform business.
For the most recent quarter's results and guidance, visit GoodRx's investor relations page directly.
GDRX Price History
-93.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in GoodRx Holdings, Inc.?
Based on GoodRx Holdings, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
GDRX Long-term Outlook
GDRX's fundamental outlook is shaped by a Weak Growth pillar alongside a Strong Risk profile. This combination suggests the company is financially stable but faces real challenges in reigniting top-line momentum. The Attractive Valuation label indicates the market may already be pricing in a cautious growth trajectory, which could limit downside while also capping near-term upside if growth drivers do not materialize.
Growth drivers
- Expansion of subscription-based revenue through GoodRx Gold
- Pharma manufacturer solutions as a growing monetization channel
- Telehealth service adoption broadening the platform's utility
Key risks
- Competitive pressure from insurers, PBMs, and pharmacy chains offering their own discount programs
- Regulatory or structural changes in drug pricing that could erode the platform's value proposition
- Sustained weakness in user growth limiting revenue recovery
GDRX vs Peers
GoodRx operates in a broader digital health landscape alongside several other technology-enabled healthcare companies.
Omada focuses on chronic disease prevention through digital coaching programs, targeting employers and health plans rather than individual pharmacy consumers.
Schrödinger applies computational physics to drug discovery, operating further upstream in the pharmaceutical pipeline compared to GoodRx's consumer-facing model.
HealthStream provides workforce development and learning management solutions to healthcare organizations, serving institutional clients rather than individual consumers.
Frequently Asked Questions
What does GoodRx do?
GoodRx operates a prescription drug price comparison platform that helps consumers find lower prices at pharmacies near them. Users access negotiated discounts through GoodRx codes at checkout. The company also offers subscription plans, telehealth services, and solutions for pharmaceutical manufacturers.
Does GDRX pay dividends?
No, GoodRx does not pay a dividend. The company has focused on reinvesting in its platform and expanding its healthcare services rather than distributing cash to shareholders. Income-focused investors should factor this into their assessment.
When does GDRX report earnings?
GoodRx reports financial results on a quarterly basis, in line with standard US-listed company practice. For exact dates and the most recent results, check the investor relations section of GoodRx's official website.
Is GDRX a good stock to buy?
UQS Score rates GDRX as Good overall. Its Strong Risk profile and Attractive Valuation are positives, but Weak Growth and Moat ratings highlight real challenges. Whether it fits your portfolio depends on your own risk tolerance and investment goals — the full pillar breakdown is available to Pro members.
Is GDRX overvalued?
Based on the UQS Valuation pillar, GDRX is rated Attractive, suggesting the stock is not expensive relative to its fundamentals at current levels. That said, valuation alone does not determine investment outcomes — growth and competitive dynamics also matter significantly.
How does GDRX compare to its competitors?
GoodRx occupies a distinct niche as a consumer-facing prescription savings platform, while peers like Omada Health, Schrödinger, and HealthStream serve different segments of the digital health market. Each company has a different business model, revenue mix, and risk profile worth evaluating independently.
What is GDRX's market cap bracket?
GoodRx is classified as a small-cap company. This means it carries more volatility risk than large- or mega-cap peers but may also offer different return characteristics for investors comfortable with smaller-company exposure in the healthcare technology space.
Who founded GoodRx?
GoodRx was co-founded by Doug Hirsch and Trevor Bezdek, along with Scott Marlette. The company was built around the idea of making prescription drug pricing transparent and accessible to everyday consumers. Founding details are widely available through public sources.
Is GDRX a long-term quality investment?
As a long-term quality indicator, GDRX's profile is mixed. Its Strong Risk pillar suggests financial resilience, but Weak Growth and Moat ratings raise questions about durable competitive advantage over time. Long-term quality investors typically look for stronger moat and growth consistency — view the full analysis on UQS Pro.
What is the main competitive advantage of GoodRx?
GoodRx's primary advantage has been its brand recognition and scale in prescription price comparison, giving it a large consumer base and pharmacy network. However, the UQS Moat pillar rates this as Weak, reflecting that the barriers to replication remain relatively low in this space.
What sector does GDRX belong to?
GoodRx operates in the Healthcare sector, specifically at the intersection of healthcare technology and consumer health services. It sits within the digital health subsegment, focusing on prescription affordability and access rather than direct care delivery.
Is GDRX a growth stock or value stock?
Based on UQS pillar labels, GDRX presents more like a value-leaning situation — its Valuation pillar is Attractive while its Growth pillar is Weak. This profile may appeal to investors seeking a discounted entry point, though weak growth momentum tempers the traditional growth-stock case.
Unlock Full GDRX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare GDRX against sector peers side by side
- ✓See how Valuation and Risk scores are calculated
- ✓Get the full analyst-style quality profile in one view
- ✓Track score changes as new earnings data arrives
Pro Analysis
GDRX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 18, 2026 | 50.6 | 45.8 | 24.0 | 38.5 | 69.4 | 100.0 | -0.4 |
| May 14, 2026 | 51.0 | 47.8 | 24.0 | 38.3 | 69.4 | 100.0 | -0.2 |
| May 12, 2026 | 51.2 | 48.7 | 24.0 | 38.3 | 69.4 | 100.0 | -2.0 |
| May 4, 2026 | 53.2 | 50.5 | 24.0 | 37.3 | 80.8 | 100.0 | +0.1 |
| Apr 25, 2026 | 53.1 | 50.5 | 24.0 | 37.0 | 80.8 | 100.0 | +0.1 |
| Apr 23, 2026 | 53.0 | 50.0 | 24.0 | 37.0 | 80.8 | 100.0 | -0.1 |
| Apr 16, 2026 | 53.1 | 50.5 | 24.0 | 37.0 | 80.8 | 100.0 | +0.5 |
| Apr 15, 2026 | 52.6 | 48.7 | 24.0 | 37.0 | 80.2 | 100.0 | -0.5 |
| Apr 11, 2026 | 53.1 | 50.5 | 24.0 | 37.0 | 80.8 | 100.0 | +0.5 |
| Apr 10, 2026 | 52.6 | 48.7 | 24.0 | 37.0 | 80.2 | 100.0 | -0.4 |
GDRX — Pillar Breakdown
Quality
— 45.8/100 (25%)GoodRx Holdings, Inc. has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 38.5/100 (20%)GoodRx Holdings, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 69.4/100 (15%)GoodRx Holdings, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 100.0/100 (15%)GoodRx Holdings, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 24/100 (25%)GoodRx Holdings, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for GDRX.
Score Composition
Financial Data
More Stock Analysis
How is the GDRX UQS Score Calculated?
The UQS (Unified Quality Score) for GoodRx Holdings, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses GoodRx Holdings, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether GoodRx Holdings, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.